Clinical Trials Logo

Pituitary Diseases clinical trials

View clinical trials related to Pituitary Diseases.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04863339 Withdrawn - Surgery Clinical Trials

Tranexamic Acid for Blood Loss Minimization in Endoscopic Pituitary Surgery

Start date: March 2022
Phase: Phase 2
Study type: Interventional

This trial is to determine the effect of Tranexamic Acid (TXA) on blood loss during endoscopic pituitary surgery. The hypothesis of this study is that TXA will reduce blood loss during surgery compared to a placebo. To answer this hypothesis, the investigators are conducting a randomized controlled trial in which half of participants will receive TXA and half will receive placebo (saline) in a double blind fashion.

NCT ID: NCT04106843 Withdrawn - Clinical trials for Metastatic Adrenal Gland Pheochromocytoma

Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers

Start date: June 13, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well 177Lu-DOTATATE works in treating patients with rare endocrine cancers that have spread from where they started to nearby tissue or lymph nodes (locally advanced), spread to other places in the body (metastatic), or cannot be removed by surgery (unresectable). Radioactive drugs, such as 177Lu-DOTATATE, may carry radiation directly to cancer cells and not harm normal cells. 177Lu-DOTATATE may help to control endocrine cancers compared to standard treatment.

NCT ID: NCT01203618 Withdrawn - Clinical trials for Resectable, Non-functioning Pituitary Adenoma

Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas

Start date: February 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate whether therapy with farletuzumab is effective and safe in the treatment of resectable, non-functioning pituitary adenomas.

NCT ID: NCT00601289 Withdrawn - Clinical trials for Brain and Central Nervous System Tumors

Temozolomide in Treating Patients With Invasive Pituitary Tumors

Start date: December 2009
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well temozolomide works in treating patients with invasive pituitary tumors.

NCT ID: NCT00003514 Withdrawn - Clinical trials for Merkel Cell Carcinoma

Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy

Start date: n/a
Phase: Phase 2
Study type: Interventional

RATIONALE: Antineoplastons are naturally-occurring substances that may also be made in the laboratory. Antineoplastons may inhibit the growth of cancer cells. PURPOSE: This phase II trial is studying how well antineoplaston therapy works in treating patients with neuroendocrine tumor that is metastatic or unlikely to respond to surgery or radiation therapy.